Work

Outcomes and Duration of Pneumocystis jiroveci Pneumonia Therapy in Infants With Severe Combined Immunodeficiency

Year: 2011

Type: article

Abstract: This retrospective review of patients with severe combined immunodeficiency and Pneumocystis jiroveci pneumonia (PCP) evaluated the relationship between duration of therapy to treat PCP and overall survival. We found that 80% of patients receiving only 21 days of antibiotics survived to 12 months beyond hematopoietic cell transplant, whereas only 25% of patients who required longer treatment for PCP survived to stem cell engraftment.

Source: The Pediatric Infectious Disease Journal

DOI: 10.1097/inf.0b013e31822db772

Authors: Ingrid S. Lundgren, Janet A. Englund, Lauri M. Burroughs, Troy R. Torgerson, Suzanne Skoda-Smith

Institutions: Seattle Children's Hospital, Fred Hutch Cancer Center

Language: English

Topic: Pneumocystis jirovecii pneumonia detection and treatment

Subfield: Epidemiology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: green

Funders: National Heart, Lung, and Blood Institute, Eunice Kennedy Shriver National Institute of Child Health and Human Development